Senate Panel Questions Early PBM Response To Repatha Price Cut
Rebate expectations appear to have got in the way of fast uptake for some of the leading pharmacy benefit managers, according to comments by executives at the Senate Finance Committee hearing April 9.
You may also be interested in...
On eve of congressional hearing, the pharmacy benefit manager assures Amgen that Repatha is available to its employees.
Drug makers remained front and center during the Senate Finance Committee's third hearing on drug pricing, even though leaders from five pharmacy benefit managers were testifying.
Executives from Eli Lilly, Novo Nordisk and Sanofi, as well as representatives from the three largest pharmacy benefit managers, will testify before the House Energy and Commerce Committee’s Subcommittee on Oversight and Investigations April 10; patients, professional organization representatives and academics at an April 2 hearing said they want to know why insulin prices remain out of reach for many diabetics.